Degrader-Antibody Conjugates (DACs) Development & Manufacturing

Establish a strong foundation with a rational design strategy that balances efficacy, stability, safety, and manufacturability.

• Target assessment
• Antibody selection and engineering
• Linker design and payload selection strategy
• Conjugation methodology selection
• Early developability assessment
• Candidate screening and optimization

Abzena’s scientists have extensive experience across antibodies, targeting proteins, conjugation chemistries, linkers, and complex payloads, enabling robust design of next generation bioconjugates.

Identify the most promising lead candidates before significant resources are invested. Our developability approach evaluates:

• Specificity
• Functionality
• Stability
• Safety
• Manufacturability

Using integrated bioassays and analytical methods, we help identify liabilities early and generate actionable data to support the confident progression of candidates.

Develop scalable and reproducible conjugation processes suitable for clinical and commercial manufacturing. Capabilities include:

• Site-specific and stochastic conjugation strategies
• Engineered cysteine, affinity peptide, and enzymatic conjugation approaches
• Process optimization and scale-up
• Conjugate purification development
• Technology transfer

Abzena has extensive experience developing robust conjugation methodologies and optimizing purification processes for bioconjugates manufacturing.

Comprehensive analytical support is essential for understanding conjugate quality and performance. Our analytical capabilities support:

• Conjugate identity confirmation
• Purity assessment
• Aggregation analysis
• Stability monitoring
• Biological activity testing

Abzena applies orthogonal analytical approaches throughout development to generate high-quality data and support informed decision-making.

Develop formulations that support stability, manufacturability, and clinical success. Services include:

• Pre-formulation assessment
• Buffer optimization
• Excipient screening
• Freeze-thaw stability studies
• Thermal stability evaluation
• Concentration optimization
• Liquid and lyophilized dosage forms

Our formulation scientists tailor development activities to your target product profile and development stage, supporting efficient progression from preclinical development to clinical manufacturing.

Transition confidently from laboratory development into manufacturing. Capabilities include:

• Process optimization
• Scale-up development
• Manufacturing-ready process design
• Purification strategy development
• Technology transfer support

Abzena’s bioconjugation facilities and expertise enable seamless progression from early-stage development through cGMP production.

Prepare your DAC program for clinical advancement with Abzena’s integrated development and manufacturing support. Services include:

• GMP-ready cell line development
• Conjugation manufacturing
• Release testing
• Quality systems support
• Regulatory and CMC support
• Clinical supply manufacturing

Our fully integrated CDMO+CRO model simplifies program management and facilitates efficient progression toward clinical milestones.